Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

NCT05887609 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05887609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05887609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Recruiting
Start date
October 3, 2023
Completion date
January 31, 2031
Enrollment
53 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovary cancer, peritoneal cancer